Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

F, Cosman; EF, Eriksen; C, Recknor; PD, Miller; N, Guañabens; C, Kasperk; P, Papanastasiou; A, Readie; H, Rao; JA, Gasser; C, Bucci-Rechtweg; S, Boonen

doi:10.1002/jbmr.238

Public

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Shared by NobleBlocks on Mar 1, 2011 • 12:00 AM UTC

Authors:

Cosman F

Eriksen EF

Recknor C

Abstract

Clinical data suggest concomitant therapy with bisphosphonates and parathyroid hormone (PTH) may blunt the anabolic effect of PTH; rodent models suggest that infrequently administered bisphosphonates may interact differently. To evaluate the effects of combination therapy with an intravenous infusio...

Discussions